Rathkopf D, Chi KN, Vaishampayan U, Hotte S, Vogelzang N, Alumkal J, Agrawal M, Nydam TM, Fandi A, Scher HI. Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 27:15s, 2009 (suppl; abstr 5064).
Rathkopf D, Carducci M, Liu G, Cheng S, Ning J, Zhou X, Reddy J, Shen Y, Fleisher M, Larson S, Wilding G, Scher HI. BMS-641988, a novel inhibitor of androgen signaling, shows potent endocrine activity in a Phase I prostate cancer study. AUA Annual Meeting, 2009.
Rathkopf D, Carducci M, Liu G, Cheng S, Ning J, Zhou X, Reddy J,Shen Y, Fleisher M, Anand A, Wilding G, Scher HI. Circulating tumor cells (CTC) in patients with castrate-resistant prostate cancer (CRPC) treated with BMS-641988, a novel inhibitor of androgen. AACR Advances in Prostate Cancer Research, 2009.
Rathkopf D, Wong BY, Ross RW, George DJ, Picus J, Tanaka E, Chen Y, Atadja P, Yang W, Culver KW, Scher HI. A phase I trial of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) in castration-resistant prostate cancer (CRPC). ESMO Annual Meeting, Switzerland, 2008.
Rathkopf D, Wong BY, Ross RW, George DJ, Picus J, Tanaka E, Chen Y, Atadja P, Yang W, Culver KW, Scher HI. A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 5152).
Rathkopf D, Wong BY, Ross RW, George DJ, Picus J, Tanaka E, Chen Y, Atadja P, Yang W, Culver KW, Scher HI. A phase I dose escalation study of oral panobinostat (LBH589) alone and in combination with IV docetaxel (Doc) and oral prednisone in castration-resistant prostate cancer (CRPC). ASCO Genitourinary Cancers Symposium. Abstract # 171; 2008.
Rathkopf D, Carducci MA, Slovin S, Morris M, Kelsen M, Eisenberger M, Baker SD, Scher HI. Docetaxel (Doc) and rapid androgen cycling for noncastrate prostate cancer patients with minimal disease. ASCO Prostate Cancer Symposium, Abstract #204; 2007.
Rathkopf D, Carducci MA, Slovin S, Morris M, Shaffer D, Eicher C, Kelsen M, Eisenberger M, Baker SD, Scher HI. A phase II trial of docetaxel (Doc) with rapid hormonal cycling for patients with non-castrate metastatic prostate cancer. ASCO Prostate Cancer Symposium. Abstract #207; 2006.
Rathkopf D, Fornier M, Shah MA, Kortmansky J, O’Reilly E, Winkelmann J, Balzano L, Kelsen DP, Schwartz GK. A Phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4096.
Rathkopf D, Fornier M, Shah M, Kortmansky J, O’Reilly E, King A, Winkelmann J, Kelsen DP, Olsen S, Schwartz G. A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 3072.
Rathkopf D, Ilson DH, Yi S, Winkelmann J, Kelsen DP, Schwartz GK. A phase II trial of sequential paclitaxel and flavopiridol in patients with metastatic paclitaxel-refractory esophageal cancer.ASCO Gastrointestinal Cancers Symposium, Abstract # 67; 2004.
